Clélia Coutzac

机构：Lyon 1 Université, Centre National de la Recherche Scientifique, Inserm, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, HCL Technologies (India) · ORCID：0000-0002-8347-6957

发表论文 105 篇 · 总被引 3854 次 · h-index 20

代表论文

• Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer (2025 · New England Journal of Medicine · 被引 96)
• Neoadjuvant immunotherapy for nonmetastatic dMMR/MSI colon cancer: a real-world retrospective AGEO study (2025 · ESMO Open · 被引 11)
• Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial (2025 · Nature Cancer · 被引 11)
• Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. (2025 · Journal of Clinical Oncology · 被引 10)
• Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials (2025 · Journal of Clinical Oncology · 被引 10)
• Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial (2025 · The Lancet Oncology · 被引 8)